Clinical Trials

260 enrolled

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06632327 2026-06-02

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

Thoracic

Lung Neoplasms

NCT06661720 2026-06-02

STRIKE

Phase 3 Recruiting

1,040 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07619599 2026-06-02

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

6 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03835819 2026-06-01

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

18 enrolled 17 charts

Endometrial Neoplasms

NCT04825990 2026-06-01

POINT

30 enrolled

Nasopharyngeal Carcinoma

NCT04858269 2026-06-01

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05231122 2026-06-01

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03402880 2026-05-29

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Extensive Stage Small Cell Lung Carcinoma

NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

25 enrolled

Turcot syndrome, Carcinoma, Ovarian Epithelial

NCT05203445 2026-05-29

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

6 enrolled 9 charts

Breast Neoplasms

NCT03219450 2026-05-28

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Other hematologic neoplasm

15 enrolled

Leukemia, Leukemia, Lymphoid

NCT06123338 2026-05-28

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 2 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07610525 2026-05-28

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

200 enrolled

Other solid neoplasmThoracic

Triple Negative Breast Neoplasms

NCT02959463 2026-05-27

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Phase 1 Completed

25 enrolled 11 charts

Mesothelioma, Malignant

NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Phase 1/2 Active not recruiting

13 enrolled 12 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT06308913 2026-05-26

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Active not recruiting

10 enrolled

BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT03095781 2026-05-22

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Phase 1 Completed

47 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1/2 Completed

17 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT06113809 2026-05-22

Palbociclib and Pembrolizumab in Sarcoma

8 enrolled

Sarcoma

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Lymphoid

Hodgkin Disease

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

182 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03144466 2026-05-20

PAPAYA

Phase 1 Terminated

1 enrolled 7 charts

Uterine Cervical Neoplasms

NCT03430700 2026-05-20

PROMPT

Phase 2 Completed

20 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast Neoplasms

NCT06246968 2026-05-20

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07264075 2026-05-20

ILLUMINE

Phase 3 Recruiting

780 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05761951 2026-05-19

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

8 enrolled

Endometrial Neoplasms

NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT04032418 2026-05-18

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer